Syndax Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the …

Biotechnology
US, Waltham [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Syndax Pharmaceuticals, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Syndax Pharmaceuticals, Inc. can't present revenue by segment

End of SNDX's Analysis
CIK: 1395937 CUSIP: 87164F105 ISIN: US87164F1057 LEI: - UEI: -
Secondary Listings
SNDX has no secondary listings inside our databases.